MDCX insider transaction filings
Medicus Pharma Ltd. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-08. Screen MDCX transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 5 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 10.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Bokhari Raza — Chief Executive Officer, Director | 1 | — | — | 2 |
| Bonner Carolyn F. — President and CFO | 1 | — | — | 2 |
| Brennan Edward J. — Chief Scientific Officer | 1 | — | — | 2 |
| Mehmud Faisal — Chief Medical Officer | 1 | — | — | 2 |
| Smith Andrew Alasdair — Chief Operating Officer | 1 | — | — | 2 |
Recent Form 4 filings — Medicus Pharma Ltd.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-08 | 4 | Bokhari Raza — Chief Executive Officer, Director | Grant/award (A): 2,941,176 @ $0.17 · Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2026-09-08 | 4 | Bonner Carolyn F. — President and CFO | Grant/award (A): 1,470,588 @ $0.17 · Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2026-09-08 | 4 | Brennan Edward J. — Chief Scientific Officer | Grant/award (A): 588,235 @ $0.17 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-09-08 | 4 | Mehmud Faisal — Chief Medical Officer | Grant/award (A): 1,470,588 @ $0.17 · Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2026-09-08 | 4 | Smith Andrew Alasdair — Chief Operating Officer | Grant/award (A): 735,294 @ $0.17 · Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Rodgers Cathy McMorris — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Raju Ajay — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Mehmud Faisal — Chief Medical Officer | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | May Sara R. — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Kaiser Larry — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Ciaruffoli Robert J. — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Brennan Edward J. — Chief Scientific Officer | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Bonner Carolyn F. — President and CFO | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | FISHMAN BARRY — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Bokhari Raza — Chief Executive Officer, Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Ashton William — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Smith Andrew Alasdair — Chief Operating Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | MAHAFFY PATRICK J — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Rodgers Cathy McMorris — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Raju Ajay — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Mehmud Faisal — Chief Medical Officer | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | May Sara R. — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Kaiser Larry — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Ciaruffoli Robert J. — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Brennan Edward J. — Chief Scientific Officer | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Bonner Carolyn F. — President and CFO | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | FISHMAN BARRY — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Bokhari Raza — Chief Executive Officer, Director | Grant/award (A): 325,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Ashton William — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Smith Andrew Alasdair — Chief Operating Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | MAHAFFY PATRICK J — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Rodgers Cathy McMorris — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Raju Ajay — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Mehmud Faisal — Chief Medical Officer | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | May Sara R. — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Kaiser Larry — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Ciaruffoli Robert J. — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Brennan Edward J. — Chief Scientific Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Bonner Carolyn F. — President and CFO | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | FISHMAN BARRY — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Bokhari Raza — Chief Executive Officer, Director | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Ashton William — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Smith Andrew Alasdair — Chief Operating Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | MAHAFFY PATRICK J — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-08-14 | 4 | Quinlan James P. — Chief Financial Officer | Option exercise (M): 125,000 @ $0.81 · Option exercise (M): 20,000 @ $2.75 · Option exercise (M): 125,000 (derivative) @ $0 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2025-07-24 | 4 | Brennan Edward J. — Chief Scientific Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-07-24 | 4 | Bonner Carolyn F. — President | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-07-24 | 4 | FISHMAN BARRY — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-07-24 | 4 | Bokhari Raza — Chief Executive Officer, Director | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2025-07-24 | 4 | Ashton William — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Medicus Pharma Ltd.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-14 | 8-K | 1.02 — Termination of a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-11 | 8-K | 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-04 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-06 | 8-K | 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-01 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MDCX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →